Anticoagulation Therapy
Ozcan Basaran
Anticoagulation Therapy - New York: BoD – Books on Demand, c2016 - 150 pages
Contents:
Comparative Biology of the Resistance to Vitamin
The Risk Factors of Thrombogenic Thrombophilia and
Management of Anticoagulation Around Cardiac Implantable
Prothrombin Complex Concentrate a General Antidote for Oral
NonVitamin K Antagonist Oral Anticoagulants in Atrial
NonVitamin K Antagonist Oral Anticoagulants Clinical Use
The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.
9789535126669 9535126660 = Common terms and phrases acenocoumarol acid anticoagulant effect anticoagulant reversal antithrombin apixaban assays assessment associated atrial fibrillation Beriplex Biochem bleeding models blood coagulation cell chiral Clin clinical clotting factors compared coumarinic cytochrome D-dimer dabigatran disease drug edoxaban efficacy embolism enantiomers enzymatic epoxide reductase factor IX factor VIIa factor Xa factor Xa inhibitors gene genetic hemorrhage hemostasis heparin heparin bridging human implantation increased infusion inhibition interaction intracranial IU/kg K-dependent coagulation factors major bleeding mechanism metabolism microsomal ml/min molecule NOACs NVAF oral anticoagulants p-GP patients pharmacokinetics phenprocoumon plasma polymorphism pregnancy procoagulant prophylaxis protein prothrombin complex concentrate recombinant factor VIIa renal reversal agent reversal of anticoagulation rivaroxaban rodenticides rodents surgery target Thromb Haemost Thromb Res thrombogenic thrombogenic risk factors thrombophilia thrombotic treatment trial venous thromboembolism venous thrombosis vitamin K vitamin K epoxide vitamin K-dependent coagulation vitamin Kantagonists vitro vivo VKOR activity VKORC1 mutations warfarin warfarin resistance
--Medical / Nursing / Pharmacology-- Medical / Critical Care --Medical › Nursing › Pharmacology
615
Anticoagulation Therapy - New York: BoD – Books on Demand, c2016 - 150 pages
Contents:
Comparative Biology of the Resistance to Vitamin
The Risk Factors of Thrombogenic Thrombophilia and
Management of Anticoagulation Around Cardiac Implantable
Prothrombin Complex Concentrate a General Antidote for Oral
NonVitamin K Antagonist Oral Anticoagulants in Atrial
NonVitamin K Antagonist Oral Anticoagulants Clinical Use
The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.
9789535126669 9535126660 = Common terms and phrases acenocoumarol acid anticoagulant effect anticoagulant reversal antithrombin apixaban assays assessment associated atrial fibrillation Beriplex Biochem bleeding models blood coagulation cell chiral Clin clinical clotting factors compared coumarinic cytochrome D-dimer dabigatran disease drug edoxaban efficacy embolism enantiomers enzymatic epoxide reductase factor IX factor VIIa factor Xa factor Xa inhibitors gene genetic hemorrhage hemostasis heparin heparin bridging human implantation increased infusion inhibition interaction intracranial IU/kg K-dependent coagulation factors major bleeding mechanism metabolism microsomal ml/min molecule NOACs NVAF oral anticoagulants p-GP patients pharmacokinetics phenprocoumon plasma polymorphism pregnancy procoagulant prophylaxis protein prothrombin complex concentrate recombinant factor VIIa renal reversal agent reversal of anticoagulation rivaroxaban rodenticides rodents surgery target Thromb Haemost Thromb Res thrombogenic thrombogenic risk factors thrombophilia thrombotic treatment trial venous thromboembolism venous thrombosis vitamin K vitamin K epoxide vitamin K-dependent coagulation vitamin Kantagonists vitro vivo VKOR activity VKORC1 mutations warfarin warfarin resistance
--Medical / Nursing / Pharmacology-- Medical / Critical Care --Medical › Nursing › Pharmacology
615